Tscan Therapeutics Is A Clinical Stage Biopharmaceutical Company Focused On Developing T Cell Receptortcrengineered T Cell Therapies For Cancer Treatmentfounded In 2018The Company Utilizes A Unique T Cell Target Discovery Platform Developed At Brigham And Womenae S Hospital And Harvard Medical Schoolthis Platform Aims To Enhance Cancer Treatment By Learning From Patients Who Are Successfully Battling The Disease The Company Specializes In Immunotherapymodifying T Cells To Effectively Recognize And Eliminate Cancer Cellsits Lead Therapy Candidatestsc 100 And Tsc 101Target Hematologic Malignanciesaiming To Prevent Relapse After Allogeneic Hematopoietic Cell Transplantationtscan Also Offers The Immunobanka Repository Of Therapeutic Tcrs For Customized Treatmentsand Is Conducting Clinical Trialsincluding The Alloha Phase 1 Heme Trial And The Plexi T Phase 1 Solid Tumor Trialto Further Advance Its Innovative Therapiesadditionallytscan Is Exploring Applications Of Its Technology In Autoimmune Disorders And Infectious Diseases
No conferences found for this company.
| Company Name | Tscan Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
